NCT06811116View on ClinicalTrials.gov

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

February 10, 2026

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood collection

DRUG

Cabozantinib S-malate

Given PO

PROCEDURE

Imaging Procedure

Undergo imaging scans

DRUG

Sapanisertib

Given orally (PO)

Trial Locations (1)

15232

RECRUITING

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH